AstraZeneca’s supplemental New Drug Application, or sNDA, for Tagrisso in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, the company announced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca call volume above normal and directionally bullish
- Genmab price target raised to $46 from $44 at BTIG
- Fusion Pharmaceuticals and AstraZeneca’s FPI-2068 shows anti-tumor efficacy
- AstraZeneca announces first data from four pivotal Phase III trials at ESMO
- Ionis announces new results from analysis of exploratory cardiac endpoints